Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Authors' conclusion
Model simulations using real-world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even from a short-term perspective.
Study context
- Population
- People with T2D and established CVD in Sweden; 30 model cohorts from national health data registers
- Participants
- 131,412 people30 model cohorts
- Exposure
- Standard of care (SoC) with empagliflozin vs SoC before empagliflozin
- Outcome
- Health benefits and costs over 3 years (100% implementation)
- Follow-up
- 3 years
Methodological detailscost-effectiveness and budget impact, validated Institute for Health Economics Diabetes Cohort Model (IHE-DCM) cohort model, 3-year budget impact and lifetime cost per quality-adjusted life years (QALY), implementation scenarios 100%/75%/50%, sensitivity analyses
- Cost-effectiveness and budget impact
- Validated IHE-DCM cohort model
- 3-year budget impact and lifetime cost per QALY
- Implementation scenarios 100%/75%/50%
- Sensitivity analyses
Main finding
As reported in the abstract
3 years
Total life years gained
7700
Reduction in cumulative incidence of cardiovascular deaths
30%
Reduction in cumulative incidence of heart failures
28%
Increase in annual costs (higher treatment costs and increased survival)
15%
Observational data: associations, not effects.
Further findings
Lifetime cost-effectiveness
- QALYs per person with SoC with empagliflozin
- 0.37
- Incremental cost-effectiveness ratio vs SoC before empagliflozin
- 16 000 EUR per QALY
Original publication
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease. Diabetes Obes Metab. Published 2 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →